stockrow
Friday 6 November 2026
Export RVPH’s income statement to Excel — free account
Reviva Pharmaceuticals Holdings, Inc.
RVPH Healthcare Biotechnology
- EPS
- +92.1%
- Free cash flow
- +57.8%
Quarter to June 2026, against a year earlier
0.37
0.03
+8.82%
Follow RVPH
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 3 | 3 | — | 0.0% | |
| Gross margin, % | — | — | — | — | 0.00 | — | — | — | — | — | — | — | ||||||
| EBT | — | — | 1 | (1) | (4) | (9) | (28) | (39) | (30) | (20) | (13) | n/m | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | 0 | (1) | (4) | (9) | (28) | (39) | (30) | (20) | (13) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | 1.39 | (6.12) | (24.80) | (11.60) | (28.96) | (33.00) | (18.00) | (5.48) | (2.42) | n/m | ||||||
| Cash flow | — | 0.00 | (0.32) | (1.58) | (26.56) | (14.42) | (19.43) | (23.80) | (19.88) | (6.78) | (1.31) | n/m | ||||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | 0.00 | (0.32) | (1.58) | (26.56) | (14.42) | (19.43) | (23.80) | (19.88) | (6.78) | (1.31) | n/m | ||||||
| Book value | — | 0.00 | 12.10 | (49.22) | 35.70 | 38.79 | 8.60 | 4.81 | 0.48 | 2.38 | 1.15 | n/m | ||||||
| Shares, m | — | — | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 4 | 7 | +36.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | 0 | 0 | (4) | (11) | (19) | (28) | (34) | (25) | (17) | +92.6% | |||||
| Capex | — | 0 | 0 | — | — | — | — | — | — | — | — | n/m | ||||||
| Free cash flow | — | 0 | 0 | 0 | (4) | (11) | (19) | (28) | (34) | (25) | (17) | +92.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 0 | 0 | (7) | 7 | 29 | 9 | 7 | 0 | 8 | 15 | +43.3% | |||||
| Net debt | — | 0 | 0 | 4 | (9) | (30) | (19) | (23) | (13) | (14) | (20) | +56.6% | ||||||
| Shareholders’ equity | — | 5 | 5 | (7) | 5 | 29 | 8 | 6 | 1 | 9 | 15 | +7.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | 0.00 | 0.88 | (2.58) | (10.84) | (42.43) | (112.31) | (184.22) | (152.63) | (126.42) | (79.46) | (126.4) pt | |||||
| ROIC | — | 0.00 | (2.04) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | 0.00 | 11.15 | 5.48 | (72.30) | (49.91) | (152.43) | (556.38) | (916.17) | (419.97) | (176.60) | (420.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 4 | 5 | 5 | 10 | 15 | 14 | 14 | — | +23.2% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Reviva Pharmaceuticals Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACXP Acurx Pharmaceuticals, Inc. | $5.3M | — (loss-making) | — | — | n/m | −2.36% (below 0%: shrinking) | — | 0.00% | Compare |
| PCSA Heatwurx Inc. | $5.1M | — (loss-making) | — | −64.29% (below 0%: shrinking) | n/m | +20.29% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SNTI Senti Biosciences, Inc. | $5.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| PULM Pulmatrix, Inc. | $5.1M | — (loss-making) | — (loss-making) | −99.86% (below 0%: shrinking) | n/m | +41.26% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CNSY Cerenome, Inc. | $5.1M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| IMNN Imunon, Inc. | $5.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | −4.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | — (loss-making) | — | — | n/m | +57.80% (above 0%: growing) | — | 0.00% | |
| CDIO Cardio Diagnostics Holdings, Inc. | $5.0M | — (loss-making) | — (loss-making) | +23.79% (above 0%: growing) | n/m | +2.59% (above 0%: growing) | 100.00% | (48,193.84%) | Compare |
| CANF Can-Fite Biopharma Ltd | $4.9M | — (loss-making) | — (loss-making) | −1.18% (below 0%: shrinking) | n/m | +12.63% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $5.1M | — | — | −64.29% | — | +0.12% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 4 November 2025
Ownership
Directors and executive officers, together
8.90%
Highbridge Capital Management, LLC
6.60%
Parag Saxena
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement